BOS
ADMS

Bingham Osborn & Scarborough’s Adamas Pharmaceuticals ADMS Stock Holding History

Bingham Osborn & Scarborough’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-34,516
Closed -$142K – 169
2020
Q3 		$142K Sell
34,516
-137,686
-80% -$533K 0.01% 161
2020
Q2 		$441K Hold
172,202
– – 0.04% 93
2020
Q1 		$498K Sell
172,202
-87,761
-34% -$393K 0.05% 87
2019
Q4 		$985K Buy
259,963
+117,900
+83% +$564K 0.08% 66
2019
Q3 		$727K Hold
142,063
– – 0.06% 73
2019
Q2 		$881K Sell
142,063
-3,850
-3% -$22.1K 0.08% 63
2019
Q1 		$1.04M Buy
145,913
+11,805
+9% +$106K 0.1% 55
2018
Q4 		$1.15M Buy
134,108
+3,850
+3% +$50.1K 0.12% 44
2018
Q3 		$2.61M Hold
130,258
– – 0.23% 32
2018
Q2 		$3.37M Sell
130,258
-746
-0.6% -$20.7K 0.32% 27
2018
Q1 		$3.13M Buy
131,004
+8,641
+7% +$272K 0.3% 28
2017
Q4 		$4.15M Buy
122,363
+533
+0.4% +$14.9K 0.38% 24
2017
Q3 		$2.58M Hold
121,830
– – 0.24% 27
2017
Q2 		$2.13M Hold
121,830
– – 0.2% 29
2017
Q1 		$2.13M Buy
121,830
+4,380
+4% +$74.6K 0.21% 30
2016
Q4 		$1.99M Sell
117,450
-117,450
-50% -$1.82M 0.21% 29
2016
Q3 		$3.85M Hold
234,900
– – 0.41% 22
2016
Q2 		$3.56M Buy
234,900
+204,900
+683% +$3.38M 0.41% 21
2016
Q1 		$434K Hold
30,000
– – 0.05% 75
2015
Q4 		$850K Hold
30,000
– – 0.1% 42
2015
Q3 		$502K Hold
30,000
– – 0.06% 65
2015
Q2 		$787K Buy
+30,000
New +$583K 0.1% 47

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Bingham Osborn & Scarborough's ADMS Position: Q4 2020 in Review

Bingham Osborn & Scarborough sold out of Adamas Pharmaceuticals (ADMS) in Q4 2020, closing a stake of 34,516 shares — an estimated $142K sold.

Bingham Osborn & Scarborough first reported a position in ADMS in Q2 2015 and held it in 22 quarters. The position peaked at $4.15M in Q4 2017. 65 funds tracked by Wall St. Rank hold ADMS as of Q4 2020.

  • Bingham Osborn & Scarborough reported no remaining Adamas Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Bingham Osborn & Scarborough sold 34,516 Adamas Pharmaceuticals shares in Q4 2020, an estimated $142K.
  • Bingham Osborn & Scarborough first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 22 quarters.
  • Bingham Osborn & Scarborough's Adamas Pharmaceuticals position peaked at $4.15M in Q4 2017.
  • 65 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2020.

Based on Bingham Osborn & Scarborough's 13F filing for Q4 2020, filed 11 Feb 2021.